POEMs and Tips

From Other Journals

Isosorbide Dinitrate Plus Hydralazine in Black Patients

Am Fam Physician. 2005 Mar 1;71(5):972-975.

Clinical Question: Does the combination of hydralazine and isosorbide dinitrate improve outcomes in black patients with systolic heart failure?

Setting: Outpatient (specialty)

Study Design: Randomized controlled trial (double-blinded)

Allocation: Concealed

Synopsis: In this manufacturer-sponsored study, investigators identified black adult patients with a left ventricular ejection fraction of no greater than 35 percent (or less than 45 percent with a reduced left ventricular internal, end-diastolic diameter). Exclusion criteria included acute myocardial infarction, acute coronary syndrome, recent stroke, recent cardiac surgery or angioplasty, valvular heart disease, or hypotension or uncontrolled hypertension. The primary outcome was a composite of death, hospitalization, and change in quality of life.

The authors took an innovative approach to assigning different weights for these outcomes. For example, death was three times as bad as a hospitalization. Allocation to groups was concealed, outcome assessment was appropriately blinded, and analysis was by intention to treat. Patients were a mean age of 57 years, 60 percent were men, and 95 percent were classified as New York Heart Association class III (i.e., moderately severe heart failure symptoms).

Patients were randomized to receive37.5mg of hydralazine plus 20 mg of isosorbide dinitrate three times daily (with that dosage doubled, if tolerated) or matching placebo. Approximately two thirds of patients achieved the final target dosage. The study ended early because of a significant benefit in the active treatment group. This benefit included a significantly lower risk of death from any cause (6.2 versus 10.2 percent; number needed to treat [NNT] = 25; 95 percent confidence interval [CI], 10 to 40), a lower likelihood of first hospitalization for heart failure (16.4 versus 24.4 percent; NNT = 12; 95 percent CI, eight to 20), and a greater improvement in quality-of-life score. Adverse effects were common in the active treatment group: primarily headache (47 versus 19 percent for placebo) and dizziness (29 versus 12 percent for placebo).

Bottom Line: The combination of hydralazine (37.5 to 75 mg) and isosorbide dinitrate (20 to 40 mg) given three times daily improves survival and quality of life, and reduces the likelihood of hospitalization in relatively young black patients with left ventricular dysfunction. (Level of Evidence: 1b)

Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.